Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva (Erlotinib Hydrochloride) in Combination With Avastin (Bevacizumab) Versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma

NCT00081614 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00081614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00081614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva (Erlotinib Hydrochloride) in Combination With Avastin (Bevacizumab) Versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2004
Completion date
July 31, 2005
Enrollment
100
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

metastases, renal cell carcinoma